Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

Sean McBride,Eric J. Sherman,C. Jillian Tsai,Shrujal S. Baxi,Jahan Aghalar,Juliana Eng,Wanqing Iris Zhi,Daniel C. McFarland,Loren S. Michel,Robert J. Young,Robert A. Lefkowitz,D. Spielsinger,Zhigang Zhang,Jessica Flynn,Lara Dunn,Alan L. Ho,Nadeem Riaz,David G. Pfister,Nancy Y. Lee

Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma.

2020

Sean McBride
Eric J. Sherman
C. Jillian Tsai
Shrujal S. Baxi
Jahan Aghalar
Juliana Eng
Wanqing Iris Zhi
Daniel C. McFarland
Loren S. Michel
Robert J. Young
Robert A. Lefkowitz
D. Spielsinger
Zhigang Zhang
Jessica Flynn
Lara Dunn
Alan L. Ho
Nadeem Riaz
David G. Pfister
Nancy Y. Lee

PURPOSEThe objective response rate (ORR) for single-agent anti–programmed death receptor 1 (anti–PD-1) therapy is modest in patients with metastatic or recurrent head and neck squamous cell carcino...

Keywords:

in patient
Medicine
Head and neck squamous-cell carcinoma
stereotactic body radiotherapy
head and neck
Oncology
objective response
Internal medicine
Nivolumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations